Heart failure & cardiomyopathies
Magnetocardiography for the Non-Invasive Diagnosis of Myocardial Inflammation in Cardiac Amyloidosis: A Proof-of-Concept Study
Authors' conclusion
This proof-of-concept study provides initial evidence for the potential of MCG as a non-invasive method to identify myocardial inflammation in patients with cardiac amyloidosis.
Study context
- Population
- Patients with cardiac amyloidosis who had undergone magnetocardiography (MCG) and endomyocardial biopsy
- Participants
- 27 patients
- Comparison
- MCG vs endomyocardial biopsy for myocardial inflammation
- Myocardial inflammationn = 10
- Outcome
- Diagnostic value of MCG for myocardial inflammation (biopsy reference)
Methodological detailsretrospective, proof-of-concept
- Retrospective
- Proof-of-concept
Performance
As reported in the abstract
Diagnosis of myocardial inflammation by VMCG
Myocardial inflammation
0.093
IQR 0.058–0.183
No myocardial inflammation
0.052
IQR 0.039–0.073
P = 0.01
- AUC of VMCG
- 0.785 (95% CI 0.600-0.970; P < 0.01)
- Optimal cut-off (Youden's index)
- VMCG ≥0.078
- Sensitivity
- 60.0%
- Specificity
- 88.2%
- PPV
- 75.0%
- NPV
- 78.9%
Original publication
Magnetocardiography for the Non-Invasive Diagnosis of Myocardial Inflammation in Cardiac Amyloidosis: A Proof-of-Concept Study. ESC Heart Fail. Published 21 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →